Literature DB >> 6086866

Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulin.

S G Paryani, A M Arvin, C M Koropchak, M B Dobkin, A E Wittek, M D Amylon, M D Budinger.   

Abstract

We compared the VZV IgG antibody titers after administration of varicella zoster immune globulin and serum immune globulin intravenously (IGIV) in VZV seronegative pediatric patients with cancer. Four patients received VZIG at standard doses; four received IGIV at 4 ml/kg every 4 weeks for four doses; and five received IGIV at 6 ml/kg every 6 weeks for two to four doses. VZV antibody titers were measured by radiommunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody assay (IFA), and neutralizing antibody assay. The mean peak and trough VZV titers by RIA were comparable in all three groups: 1:724 at 4 weeks after VZIG, 1:2048 at 4 weeks after 4 ml/kg IGIV, and 1:776 at 6 weeks after 6 ml/kg IGIV. The titers measured by ELISA, IFA, and neutralizing antibody were comparable after VZIG or IGIV. The VZV titers by RIA were maintained at greater than or equal to 1:1024 after subsequent doses of 4 ml/kg IGIV, and at greater than or equal to 1:256 after subsequent doses of 6 ml/kg IGIV. Adverse effects were rare. The VZV antibody titers assessed 4 to 6 weeks after IGIV administration were equivalent to the titers measured 4 weeks after administration of VZIG.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086866     DOI: 10.1016/s0022-3476(84)80113-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin.

Authors:  Arlan Cohen; Panagis Moschopoulos; Panagis Maschopoulos; Richard E Stiehm; Gideon Koren
Journal:  CMAJ       Date:  2011-01-24       Impact factor: 8.262

2.  Steroid Sensitive Nephrotic Syndrome: Revised Guidelines.

Authors:  Aditi Sinha; Arvind Bagga; Sushmita Banerjee; Kirtisudha Mishra; Amarjeet Mehta; Indira Agarwal; Susan Uthup; Abhijeet Saha; Om Prakash Mishra
Journal:  Indian Pediatr       Date:  2021-03-20       Impact factor: 1.411

3.  Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge.

Authors:  Christine Meyer; Flora Engelmann; Nicole Arnold; David L Krah; Jan ter Meulen; Kristen Haberthur; Jesse Dewane; Ilhem Messaoudi
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

Review 4.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

5.  Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques.

Authors:  Kristen Haberthur; Aubrey Kraft; Nicole Arnold; Byung Park; Christine Meyer; Mark Asquith; Jesse Dewane; Ilhem Messaoudi
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

6.  CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.

Authors:  Kristen Haberthur; Flora Engelmann; Byng Park; Alex Barron; Alfred Legasse; Jesse Dewane; Miranda Fischer; Amelia Kerns; Monica Brown; Ilhem Messaoudi
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

7.  Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination.

Authors:  Rohiverth Guarecuco; Jennifer Lu; Kevin J McHugh; James J Norman; Lavanya S Thapa; Emily Lydon; Robert Langer; Ana Jaklenec
Journal:  Vaccine       Date:  2017-06-19       Impact factor: 3.641

8.  Biological response modifiers and infectious diseases: actual and potential therapeutic agents.

Authors:  J J Rusthoven
Journal:  Int J Antimicrob Agents       Date:  1994       Impact factor: 5.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.